Skip to main content
Top
Published in: Diabetologia 8/2006

01-08-2006 | Article

Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study

Authors: A. W. K. Tso, P. C. Sham, N. M. S. Wat, A. Xu, B. M. Y. Cheung, R. Rong, C. H. Y. Fong, J. Y. Xu, K. K. Y. Cheng, E. D. Janus, K. S. L. Lam

Published in: Diabetologia | Issue 8/2006

Login to get access

Abstract

Aims/hypothesis

Polymorphisms of the gene encoding adiponectin (ADIPOQ) have previously been associated with type 2 diabetes in Europid and Japanese subjects, but not in Pima Indians. The aim of this study was to determine the contribution made by ADIPOQ gene variants to glycaemic status in southern Chinese individuals.

Subjects and methods

Sixty unrelated subjects were screened for single-nucleotide polymorphisms (SNPs) in the ADIPOQ gene by direct sequencing. The association of tagging SNPs with the outcome of glycaemic status in 262 subjects with impaired glucose tolerance (IGT) was examined in a 5-year prospective study.

Results

We identified 15 polymorphisms in the ADIPOQ gene, ten of them constituting the tagging SNPs. At 5 years, 39.7% of the subjects with IGT had regressed to NGT, 41.2% had persistent IGT or impaired fasting glucose and 19.1% had developed diabetes. Only the T45G polymorphism was associated with persistent hyperglycaemia at 5 years (p=0.001). Haplotypes formed by the addition of other SNPs, as haplotype blocks or pairs, did not confer greater association than T45G alone. On logistic regression analysis, T45G independently predicted persistent hyperglycaemia at 5 years (OR=2.25, 95% CI 1.29–3.95, G carriers vs TT; p=0.005). It also predicted persistent hyperglycaemia in a nested case–control study involving 158 sex- and age-matched controls with persistent NGT (p=0.012, adjusted for BMI), and that of diabetes or glycaemia progression (p<0.05) in a meta-analysis that also included two published studies in Europid subjects.

Conclusions/interpretation

Our findings support a significant role of this common ADIPOQ gene polymorphism in predicting glycaemic status in southern Chinese people.
Literature
1.
go back to reference Fruebis J, Tsao TS, Javorschi S et al (2001) Proteolytic cleavage product of 30-kDa adipocytes complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMedCrossRef Fruebis J, Tsao TS, Javorschi S et al (2001) Proteolytic cleavage product of 30-kDa adipocytes complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMedCrossRef
2.
go back to reference Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMedCrossRef Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMedCrossRef
3.
go back to reference Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946PubMedCrossRef Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946PubMedCrossRef
4.
go back to reference Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinaemia. J Clin Endocrinol Metab 86:1930–1935PubMedCrossRef Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinaemia. J Clin Endocrinol Metab 86:1930–1935PubMedCrossRef
5.
go back to reference Takahashi M, Arita Y, Yamagata K et al (2000) Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24:861–868PubMedCrossRef Takahashi M, Arita Y, Yamagata K et al (2000) Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24:861–868PubMedCrossRef
6.
go back to reference Vionnet N, Hani EH, Dupont S et al (2000) Genome-wide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-24. Am J Hum Genet 67:1470–1480PubMedCrossRef Vionnet N, Hani EH, Dupont S et al (2000) Genome-wide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-24. Am J Hum Genet 67:1470–1480PubMedCrossRef
7.
go back to reference Hara K, Boutin P, Mori Y et al (2002) Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536–540PubMedCrossRef Hara K, Boutin P, Mori Y et al (2002) Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536–540PubMedCrossRef
8.
go back to reference Vasseur F, Helbecque N, Dina C et al (2002) Single-nucleotide polymorphism haplotypes in both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 11:2607–2614PubMedCrossRef Vasseur F, Helbecque N, Dina C et al (2002) Single-nucleotide polymorphism haplotypes in both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 11:2607–2614PubMedCrossRef
9.
go back to reference Gu HF, Abulaiti A, Östenson C et al (2004) Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians. Diabetes 53(Suppl 1):S31–S35PubMedCrossRef Gu HF, Abulaiti A, Östenson C et al (2004) Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians. Diabetes 53(Suppl 1):S31–S35PubMedCrossRef
10.
go back to reference Stumvoll M, Tschritter O, Fritsche A et al (2002) Association of the T–G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity. Diabetes 51:37–41PubMedCrossRef Stumvoll M, Tschritter O, Fritsche A et al (2002) Association of the T–G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity. Diabetes 51:37–41PubMedCrossRef
11.
go back to reference Menzaghi C, Ercolino T, Paola RD et al (2002) A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 51:2306–2312PubMedCrossRef Menzaghi C, Ercolino T, Paola RD et al (2002) A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 51:2306–2312PubMedCrossRef
12.
go back to reference Wat NM, Lam TH, Janus ED, Lam KS (2001) Central obesity predicts the worsening of glycemia in southern Chinese. Int J Obes Relat Metab Disord 25:1789–1793PubMedCrossRef Wat NM, Lam TH, Janus ED, Lam KS (2001) Central obesity predicts the worsening of glycemia in southern Chinese. Int J Obes Relat Metab Disord 25:1789–1793PubMedCrossRef
13.
go back to reference Tan KC, Wat NM, Tam SC, Janus ED, Lam TH, Lam KS (2003) C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care 26:2323–2328PubMedCrossRef Tan KC, Wat NM, Tam SC, Janus ED, Lam TH, Lam KS (2003) C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care 26:2323–2328PubMedCrossRef
14.
go back to reference Alberti KGMM, Zimmet PZ; for the WHO Consultation (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabetic Med 15:539–553PubMedCrossRef Alberti KGMM, Zimmet PZ; for the WHO Consultation (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabetic Med 15:539–553PubMedCrossRef
15.
go back to reference Xu A, Chan KW, Hoo RLC et al (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18341–18347PubMed Xu A, Chan KW, Hoo RLC et al (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18341–18347PubMed
16.
go back to reference Zacharova J, Chiasson J, Laakso M; the STOP-NIDDM Study Group (2005) The common polymorphisms (single nucleotide polymorphism [SNP]+45 and SNP+276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes. Diabetes 54:893–899PubMedCrossRef Zacharova J, Chiasson J, Laakso M; the STOP-NIDDM Study Group (2005) The common polymorphisms (single nucleotide polymorphism [SNP]+45 and SNP+276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes. Diabetes 54:893–899PubMedCrossRef
17.
go back to reference Fumeron F, Aubert R, Siddiq A et al; for the Epidemiologic Data on the Insulin Resistance Syndrome (DESIR) Study Group (2004) Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period. The Epidemiologic Data on the Insulin Resistance Syndrome Prospective Study. Diabetes 53:1150–1157PubMedCrossRef Fumeron F, Aubert R, Siddiq A et al; for the Epidemiologic Data on the Insulin Resistance Syndrome (DESIR) Study Group (2004) Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period. The Epidemiologic Data on the Insulin Resistance Syndrome Prospective Study. Diabetes 53:1150–1157PubMedCrossRef
18.
go back to reference Hu FB, Doria A, Meigs JB et al (2004) Genetic variation of the adiponectin locus and risk of type 2 diabetes in women. Diabetes 53:209–231PubMedCrossRef Hu FB, Doria A, Meigs JB et al (2004) Genetic variation of the adiponectin locus and risk of type 2 diabetes in women. Diabetes 53:209–231PubMedCrossRef
19.
go back to reference Vozarova de Courten B, Hansoon RL, Funahashi T et al (2005) Common polymorphisms in the adiponectin gene ACDC are not associated with diabetes in Pima Indians. Diabetes 54:284–289PubMedCrossRef Vozarova de Courten B, Hansoon RL, Funahashi T et al (2005) Common polymorphisms in the adiponectin gene ACDC are not associated with diabetes in Pima Indians. Diabetes 54:284–289PubMedCrossRef
20.
go back to reference Yang WS, Tsou PL, Lee WJ et al (2003) Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity. J Mol Med 81:428–434PubMedCrossRef Yang WS, Tsou PL, Lee WJ et al (2003) Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity. J Mol Med 81:428–434PubMedCrossRef
21.
go back to reference Ohashi K, Ouchi N, Kihara S et al (2004) Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 43:1195–2000PubMedCrossRef Ohashi K, Ouchi N, Kihara S et al (2004) Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 43:1195–2000PubMedCrossRef
22.
go back to reference Yang WS, Hsiung CA, Ho LT et al; The Sapphire Study Group (2003) Genetic epistasis of adiponectin and PPARγ2 genotypes in modulation of insulin sensitivity: a family-based association study. Diabetologia 46:977–983PubMedCrossRef Yang WS, Hsiung CA, Ho LT et al; The Sapphire Study Group (2003) Genetic epistasis of adiponectin and PPARγ2 genotypes in modulation of insulin sensitivity: a family-based association study. Diabetologia 46:977–983PubMedCrossRef
23.
go back to reference Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRef Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRef
24.
go back to reference Kosaka K, Noda M, Kuzuya T (2005) Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67:152–162PubMedCrossRef Kosaka K, Noda M, Kuzuya T (2005) Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67:152–162PubMedCrossRef
25.
go back to reference Harris MI (1996) Impaired glucose tolerance—prevalence and conversion to NIDDM. Diabet Med 13(Suppl 2):S9–S11PubMed Harris MI (1996) Impaired glucose tolerance—prevalence and conversion to NIDDM. Diabet Med 13(Suppl 2):S9–S11PubMed
Metadata
Title
Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study
Authors
A. W. K. Tso
P. C. Sham
N. M. S. Wat
A. Xu
B. M. Y. Cheung
R. Rong
C. H. Y. Fong
J. Y. Xu
K. K. Y. Cheng
E. D. Janus
K. S. L. Lam
Publication date
01-08-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0324-2

Other articles of this Issue 8/2006

Diabetologia 8/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine